Transcatheter intraarterial therapies: Rationale and overview

Robert J Lewandowski, Jean Francois Geschwind, Eleni Liapi, Riad Salem

Research output: Contribution to journalReview article

126 Citations (Scopus)

Abstract

Transcatheter intraarterial therapies have proved valuable in the battle against primary and secondary hepatic malignancies. The unique aspects of all such therapies are their reduced toxicity profiles and highly effective tumor responses. These unique characteristics coupled with their minimally invasive nature provide an attractive therapeutic option in patients who may have previously had few alternatives. The concept of all catheter-based intraarterial therapies is to selectively deliver anticancer treatment to tumor(s). These therapies, which include transarterial embolization, intraarterial chemoinfusion, transarterial chemoembolization with or without drug-eluting beads, and radioembolization with use of yttrium 90, inflict lethal insult to tumors while preserving normal hepatic parenchyma. This is possible because hepatic neoplasms preferentially derive their blood supply from an arterial source while the majority of noncancerous liver is supplied by the portal vein. As part of the interventional oncology review series, in this article we describe the rationale behind each of these transcatheter therapies and provide a review of the existing medical literature.

Original languageEnglish (US)
Pages (from-to)641-657
Number of pages17
JournalRadiology
Volume259
Issue number3
DOIs
StatePublished - Jun 1 2011

Fingerprint

Therapeutics
Liver
Neoplasms
Yttrium
Liver Neoplasms
Portal Vein
Catheters
Pharmaceutical Preparations

ASJC Scopus subject areas

  • Radiology Nuclear Medicine and imaging

Cite this

Lewandowski, Robert J ; Geschwind, Jean Francois ; Liapi, Eleni ; Salem, Riad. / Transcatheter intraarterial therapies : Rationale and overview. In: Radiology. 2011 ; Vol. 259, No. 3. pp. 641-657.
@article{00f6c91a25d3406ba26e3f85f6ef57bf,
title = "Transcatheter intraarterial therapies: Rationale and overview",
abstract = "Transcatheter intraarterial therapies have proved valuable in the battle against primary and secondary hepatic malignancies. The unique aspects of all such therapies are their reduced toxicity profiles and highly effective tumor responses. These unique characteristics coupled with their minimally invasive nature provide an attractive therapeutic option in patients who may have previously had few alternatives. The concept of all catheter-based intraarterial therapies is to selectively deliver anticancer treatment to tumor(s). These therapies, which include transarterial embolization, intraarterial chemoinfusion, transarterial chemoembolization with or without drug-eluting beads, and radioembolization with use of yttrium 90, inflict lethal insult to tumors while preserving normal hepatic parenchyma. This is possible because hepatic neoplasms preferentially derive their blood supply from an arterial source while the majority of noncancerous liver is supplied by the portal vein. As part of the interventional oncology review series, in this article we describe the rationale behind each of these transcatheter therapies and provide a review of the existing medical literature.",
author = "Lewandowski, {Robert J} and Geschwind, {Jean Francois} and Eleni Liapi and Riad Salem",
year = "2011",
month = "6",
day = "1",
doi = "10.1148/radiol.11081489",
language = "English (US)",
volume = "259",
pages = "641--657",
journal = "Radiology",
issn = "0033-8419",
publisher = "Radiological Society of North America Inc.",
number = "3",

}

Transcatheter intraarterial therapies : Rationale and overview. / Lewandowski, Robert J; Geschwind, Jean Francois; Liapi, Eleni; Salem, Riad.

In: Radiology, Vol. 259, No. 3, 01.06.2011, p. 641-657.

Research output: Contribution to journalReview article

TY - JOUR

T1 - Transcatheter intraarterial therapies

T2 - Rationale and overview

AU - Lewandowski, Robert J

AU - Geschwind, Jean Francois

AU - Liapi, Eleni

AU - Salem, Riad

PY - 2011/6/1

Y1 - 2011/6/1

N2 - Transcatheter intraarterial therapies have proved valuable in the battle against primary and secondary hepatic malignancies. The unique aspects of all such therapies are their reduced toxicity profiles and highly effective tumor responses. These unique characteristics coupled with their minimally invasive nature provide an attractive therapeutic option in patients who may have previously had few alternatives. The concept of all catheter-based intraarterial therapies is to selectively deliver anticancer treatment to tumor(s). These therapies, which include transarterial embolization, intraarterial chemoinfusion, transarterial chemoembolization with or without drug-eluting beads, and radioembolization with use of yttrium 90, inflict lethal insult to tumors while preserving normal hepatic parenchyma. This is possible because hepatic neoplasms preferentially derive their blood supply from an arterial source while the majority of noncancerous liver is supplied by the portal vein. As part of the interventional oncology review series, in this article we describe the rationale behind each of these transcatheter therapies and provide a review of the existing medical literature.

AB - Transcatheter intraarterial therapies have proved valuable in the battle against primary and secondary hepatic malignancies. The unique aspects of all such therapies are their reduced toxicity profiles and highly effective tumor responses. These unique characteristics coupled with their minimally invasive nature provide an attractive therapeutic option in patients who may have previously had few alternatives. The concept of all catheter-based intraarterial therapies is to selectively deliver anticancer treatment to tumor(s). These therapies, which include transarterial embolization, intraarterial chemoinfusion, transarterial chemoembolization with or without drug-eluting beads, and radioembolization with use of yttrium 90, inflict lethal insult to tumors while preserving normal hepatic parenchyma. This is possible because hepatic neoplasms preferentially derive their blood supply from an arterial source while the majority of noncancerous liver is supplied by the portal vein. As part of the interventional oncology review series, in this article we describe the rationale behind each of these transcatheter therapies and provide a review of the existing medical literature.

UR - http://www.scopus.com/inward/record.url?scp=79956332209&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=79956332209&partnerID=8YFLogxK

U2 - 10.1148/radiol.11081489

DO - 10.1148/radiol.11081489

M3 - Review article

C2 - 21602502

AN - SCOPUS:79956332209

VL - 259

SP - 641

EP - 657

JO - Radiology

JF - Radiology

SN - 0033-8419

IS - 3

ER -